Clinical research on the treatment of locally advanced lung cancer: final report of VALG Protocol 13 Limited.
D000230:Adenocarcinoma / Q000628:therapy*; D001853:Bone Marrow / Q000187:drug effects; D018288:Carcinoma, Small Cell / Q000628:therapy*; D002294:Carcinoma, Squamous Cell / Q000628:therapy*; D002986:Clinical Trials as Topic; D004307:Dose-Response Relationship, Radiation; D004317:Doxorubicin / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D004941:Esophagitis / Q000209:etiology; D006801:Humans; D006918:Hydroxyurea / Q000009:adverse effects / Q000627:therapeutic use*; D008130:Lomustine / Q000009:adverse effects / Q000627:therapeutic use*; D008175:Lung Neoplasms / Q000628:therapy*; D008297:Male; D009607:Nitrosourea Compounds / Q000627:therapeutic use*; D011832:Radiation Injuries / Q000209:etiology; D011882:Radiotherapy, High-Energy; D012075:Remission, Spontaneous; D013997:Time Factors
D009607:Nitrosourea Compounds; D008130:Lomustine; D004317:Doxorubicin; D006918:Hydroxyurea